GO:2000357 negative regulation of kidney smooth muscle cell differentiation: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000357 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of kidney smooth muscle cell differentiation.
• Loss of negative regulation in this process permits vascular smooth muscle cells to undergo osteogenic-like phenotypic switching, a hallmark of vascular calcification in chronic kidney disease.
• Key molecular brakes include the paraspeckle protein NONO, which represses BMP2 transcription, and GDF10, a secreted negative regulator of calcification.
• MicroRNA-29a-5p and transcription factors such as FoxO3a and EGR2 modulate the balance between myofibroblast and smooth muscle phenotypes in kidney and cardiovascular tissues.
• Proteasome activator PA200 and Notch signaling temporally regulate myofibroblast and smooth muscle differentiation programs relevant to kidney vascular remodeling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate genes causally regulate this process in kidney cells.
Description
GO:2000357, negative regulation of kidney smooth muscle cell differentiation, is a biological process term that captures the active suppression of the program by which precursor cells acquire a kidney smooth muscle cell fate. In the kidney vasculature, smooth muscle cells are not terminally fixed; they can dedifferentiate or transdifferentiate toward osteogenic, myofibroblast, or synthetic phenotypes under pathological stress. The negative regulation of this differentiation process therefore acts as a brake that preserves vascular tone and prevents ectopic mineralization. Understanding this term is critical because failure of these brakes is mechanistically linked to vascular calcification, arteriovenous fistula maturation failure, and chronic kidney disease progression. At the molecular level, negative regulation of kidney smooth muscle cell differentiation is enforced by transcription factors, secreted ligands, microRNAs, and proteasome-associated proteins that antagonize pro-differentiation or pro-osteogenic signals. For example, the paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription, thereby limiting osteogenic conversion of smooth muscle lineage cells. Similarly, GDF10 acts as a negative regulator of vascular calcification, opposing the phenotypic switch that would otherwise drive mineral deposition. For researchers, GO:2000357 provides a formal ontology anchor for designing experiments that test causality: does a candidate gene suppress kidney smooth muscle cell differentiation, and through which downstream effectors? This article integrates the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease links, and CRISPR-based research strategies relevant to this term.
negative regulation of kidney smooth muscle cell differentiation At A Glance
| GO ID | GO:2000357 |
|---|---|
| GO term | negative regulation of kidney smooth muscle cell differentiation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Suppresses the frequency, rate, or extent of kidney smooth muscle cell differentiation |
| Biological context | Kidney vasculature, vascular smooth muscle phenotype switching, calcification |
| Key regulators | NONO, GDF10, miR-29a-5p, FoxO3a, PA200, Notch, EGR2 |
| Disease relevance | Vascular calcification, chronic kidney disease, arteriovenous fistula maturation |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, imaging, proteomics |
What Is GO:2000357?
According to the QuickGO definition, GO:2000357 refers to any process that stops, prevents, or reduces the frequency, rate, or extent of kidney smooth muscle cell differentiation. In practical terms, it is an inhibitory biological process that blocks precursor cells from becoming mature kidney smooth muscle cells, or that reverses or limits the expression of smooth muscle differentiation markers in kidney vascular tissue.
Why Is negative regulation of kidney smooth muscle cell differentiation Important in Cell Biology?
GO:2000357 matters because the negative regulation of kidney smooth muscle cell differentiation is a protective checkpoint against pathological phenotypic switching in the kidney vasculature. When this checkpoint fails, smooth muscle cells can adopt osteogenic or myofibroblast-like programs that promote vascular calcification and compromise vascular access in chronic kidney disease. Understanding the molecular brakes that enforce this negative regulation can reveal therapeutic targets and biomarkers for calcification, fistula maturation, and kidney vascular disease.
• Prevents osteogenic conversion of vascular smooth muscle cells in the kidney, a key step in vascular calcification.
• Preserves contractile smooth muscle identity and vascular tone in kidney arterioles and arteries.
• Modulates arteriovenous fistula maturation, a critical access procedure in dialysis patients.
• Involves secreted factors such as GDF10 that can be targeted or measured as biomarkers.
• Requires tight transcriptional control, including NONO-mediated repression of BMP2.
• Is influenced by microRNAs such as miR-29a-5p that regulate osteogenic phenotype transformation.
• Intersects with proteasome and Notch signaling pathways that time myofibroblast and smooth muscle differentiation.
• Provides a conceptual framework for CRISPR screens to identify novel suppressors of kidney smooth muscle differentiation.
• Links basic vascular biology to chronic kidney disease complications and cardiovascular risk.
• Supports development of cell models for drug testing and mechanistic studies of calcification inhibitors.
What Happens During negative regulation of kidney smooth muscle cell differentiation?
Initiation of inhibitory signals
In simple terms: The process starts when molecules that block smooth muscle differentiation are turned on or activated.
Negative regulation of kidney smooth muscle cell differentiation is initiated by extracellular and intracellular signals that oppose pro-differentiation or pro-osteogenic cues. For instance, GDF10 acts as a secreted negative regulator of vascular calcification, and its presence limits the phenotypic switch of smooth muscle lineage cells. Similarly, the paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription, thereby reducing a key osteogenic driver. These initiating signals set the stage for downstream transcriptional and post-transcriptional events that suppress smooth muscle differentiation programs.
Transcriptional repression of differentiation genes
In simple terms: Inside the nucleus, repressor proteins switch off genes that would otherwise make the cell become a smooth muscle cell.
Once inhibitory signals are engaged, transcription factors and co-repressors downregulate genes required for smooth muscle cell differentiation. NONO-mediated repression of BMP2 transcription is a concrete example: by lowering BMP2 levels, NONO reduces osteogenic signaling that would otherwise drive smooth muscle cells toward a calcifying phenotype. FoxO3a has been described as a negative regulator of cardiac myofibroblast conversion induced by TGF-beta1, illustrating how forkhead transcription factors can oppose mesenchymal differentiation programs relevant to kidney vascular cells. These transcriptional events reduce the expression of smooth muscle markers and favor a quiescent or synthetic state.
MicroRNA and post-transcriptional control
In simple terms: Small RNA molecules fine-tune the process by degrading or blocking messages from differentiation genes.
Post-transcriptional regulation by microRNAs is an important layer of negative control. miR-29a-5p has been implicated in osteogenic phenotype transformation and cellular regulation of vascular smooth muscle cells, influencing calcification in chronic kidney disease. By targeting mRNAs that promote osteogenic or synthetic phenotypes, microRNAs such as miR-29a-5p can reinforce the negative regulation of kidney smooth muscle cell differentiation. This layer allows rapid, reversible tuning of the differentiation program in response to changing local cues.
Proteasome and temporal signaling modulation
In simple terms: Protein degradation and timing signals ensure that differentiation factors are removed at the right moment.
The proteasome activator PA200 regulates myofibroblast differentiation, indicating that regulated protein turnover participates in controlling mesenchymal cell fate decisions. Notch signaling also shows temporal regulation that improves arteriovenous fistula maturation, suggesting that the timing of Notch activation influences smooth muscle and myofibroblast differentiation in vascular remodeling. Together, these mechanisms provide checkpoints that can stop or reduce kidney smooth muscle cell differentiation when appropriate.
Integration with vascular remodeling
In simple terms: The final outcome is a blood vessel that keeps its normal muscle coat instead of turning into bone-like tissue.
The integrated outcome of negative regulation of kidney smooth muscle cell differentiation is maintenance of a contractile, non-calcifying smooth muscle phenotype in the kidney vasculature. EGR2 promotes vascular smooth muscle cell differentiation and proliferation during outward remodeling in arteriovenous fistula maturation, highlighting the balance between positive and negative regulators. When negative regulation dominates or is appropriately timed, it prevents excessive osteogenic conversion and supports functional vascular remodeling.
Key Genes Involved in GO:2000357 negative regulation of kidney smooth muscle cell differentiation
The following genes and proteins have been experimentally linked to the negative regulation of kidney smooth muscle cell differentiation or closely related vascular smooth muscle phenotype control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NONO | Paraspeckle protein that inhibits BMP2 transcription and attenuates vascular calcification | Key transcriptional repressor of osteogenic conversion in smooth muscle lineage cells |
| BMP2 | Osteogenic cytokine whose transcription is repressed by NONO | Downstream effector of negative regulation; target for calcification studies |
| GDF10 | Secreted negative regulator of vascular calcification | Potential therapeutic or biomarker for calcification prevention |
| miR-29a-5p | MicroRNA involved in osteogenic phenotype transformation and calcification in VSMCs | Post-transcriptional regulator in chronic kidney disease models |
| FoxO3a | Forkhead transcription factor acting as negative regulator of myofibroblast conversion | Model for transcriptional repression of mesenchymal differentiation |
| PA200 | Proteasome activator regulating myofibroblast differentiation | Links protein turnover to smooth muscle and myofibroblast fate |
| Notch receptors | Temporal signaling regulators of arteriovenous fistula maturation | Timing of Notch activation influences vascular smooth muscle differentiation |
| EGR2 | Transcription factor promoting vascular smooth muscle cell differentiation and proliferation | Positive regulator that balances negative regulation during remodeling |
| TGF-beta1 | Cytokine that induces myofibroblast conversion and is opposed by FoxO3a | Upstream signal whose repression supports negative regulation |
| Vitamin D receptor pathway | Vitamin D physiology influences mineral and vascular biology | Context for calcification and differentiation studies |
| Runx2 (contextual) | Osteogenic transcription factor often downstream of BMP2 | Readout of osteogenic conversion in smooth muscle cells |
| SM22-alpha (contextual) | Smooth muscle differentiation marker | Marker used to assess loss of smooth muscle phenotype |
| ACTA2 (contextual) | Smooth muscle actin, contractile marker | Marker for smooth muscle differentiation status |
| Osterix (contextual) | Osteogenic transcription factor | Marker of osteogenic switch in calcifying VSMCs |
| MGP (contextual) | Matrix Gla protein, inhibitor of calcification | Functional readout of calcification suppression |
| Fetuin-A (contextual) | Circulating calcification inhibitor | Systemic factor influencing vascular calcification |
| Klotho (contextual) | Kidney-derived factor protecting against calcification | Kidney-specific context for negative regulation |
| FGF23 (contextual) | Phosphate-regulating hormone linked to calcification | Endocrine link between kidney and vascular phenotype |
How Is negative regulation of kidney smooth muscle cell differentiation Regulated?
The negative regulation of kidney smooth muscle cell differentiation is controlled by a multilayered network. Transcriptional repression via NONO and BMP2 inhibition provides a direct brake on osteogenic signaling. Secreted factors such as GDF10 act extracellularly to limit calcification and phenotypic switching. Post-transcriptional control by miR-29a-5p fine-tunes osteogenic transformation in vascular smooth muscle cells under chronic kidney disease conditions. Protein turnover through the PA200 proteasome activator and temporal Notch signaling add further regulatory layers that determine whether cells differentiate or remain quiescent. FoxO3a-mediated repression of TGF-beta1-induced myofibroblast conversion illustrates how cytokine signaling is counterbalanced by transcription factors. Together, these mechanisms ensure that kidney smooth muscle cells do not inappropriately differentiate or transdifferentiate under normal conditions.
negative regulation of kidney smooth muscle cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NONO | Vascular calcification, chronic kidney disease | CRISPR knockout in vascular smooth muscle cells followed by calcification assays |
| GDF10 | Vascular calcification | Overexpression and knockout in VSMC cultures and mouse models |
| miR-29a-5p | Osteogenic transformation in chronic kidney disease | Mimic and inhibitor transfection in VSMCs under high-phosphate conditions |
| FoxO3a | Myofibroblast conversion, fibrosis | Knockout and overexpression in fibroblast and smooth muscle cell models |
| PA200 | Myofibroblast differentiation, fibrotic remodeling | Proteasome activator knockout models with differentiation readouts |
Vascular calcification in chronic kidney disease
Vascular calcification is a major complication of chronic kidney disease and is driven in part by osteogenic conversion of vascular smooth muscle cells. Loss of negative regulation of kidney smooth muscle cell differentiation permits BMP2-driven osteogenic programs, and NONO-mediated repression of BMP2 is protective. miR-29a-5p dysregulation is also linked to osteogenic phenotype transformation and calcification in VSMCs in chronic kidney disease. GDF10 functions as a negative regulator of vascular calcification, further supporting the idea that endogenous brakes on smooth muscle differentiation protect against mineral deposition.
Arteriovenous fistula maturation failure
Arteriovenous fistulas are critical vascular accesses for hemodialysis, and their maturation depends on coordinated smooth muscle and myofibroblast differentiation. Temporal regulation of Notch activation improves arteriovenous fistula maturation, indicating that timing of differentiation signals is crucial. EGR2 promotes vascular smooth muscle cell differentiation and proliferation during outward remodeling in fistula maturation, highlighting the balance between positive and negative regulators. Disruption of negative regulation could therefore contribute to fistula failure by promoting excessive or mistimed differentiation.
Fibrotic and myofibroblast-associated remodeling
Myofibroblast conversion is a key fibrotic process that can be opposed by negative regulators. FoxO3a acts as a negative regulator of cardiac myofibroblast conversion induced by TGF-beta1, providing a paradigm for how transcription factors suppress mesenchymal differentiation. PA200 regulates myofibroblast differentiation, linking proteasome activity to fibrotic remodeling. In the kidney, failure of such negative regulation could promote fibrosis and loss of normal smooth muscle function.
Mineral and vitamin D biology
Vitamin D physiology influences mineral homeostasis and vascular biology, providing systemic context for calcification risk. Kidney-derived factors such as Klotho and FGF23 modulate phosphate and mineral metabolism, indirectly affecting vascular smooth muscle phenotype. These endocrine inputs intersect with local negative regulation of kidney smooth muscle cell differentiation to determine whether vessels remain healthy or calcify.
From negative regulation of kidney smooth muscle cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NONO increase osteogenic conversion of kidney smooth muscle cells? | CRISPR knockout of NONO in vascular smooth muscle cells with BMP2 and calcification readouts |
| Can GDF10 overexpression prevent vascular calcification? | Knock-in or overexpression of GDF10 in VSMC and mouse calcification models |
| Does miR-29a-5p directly regulate osteogenic genes in chronic kidney disease? | Point mutation of miR-29a-5p binding sites or mimic/inhibitor studies |
| Is FoxO3a required to suppress TGF-beta1-induced myofibroblast conversion? | FoxO3a knockout and rescue in fibroblast differentiation assays |
| How does PA200 proteasome activity affect myofibroblast differentiation? | PA200 knockout with proteasome activity and differentiation markers |
| Does timed Notch activation improve fistula maturation? | Inducible Notch knock-in or temporal activation in arteriovenous fistula models |
How to Study the negative regulation of kidney smooth muscle cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify differentiation and osteogenic gene programs after gene knockout |
| Alizarin red staining | Calcium deposition | Quantify vascular calcification in VSMC cultures |
| Co-immunoprecipitation | Protein-protein interactions | Map NONO and PA200 complexes |
| Immunofluorescence | Protein localization and marker expression | Assess smooth muscle versus osteogenic phenotype |
| Western blot | Protein levels of differentiation markers | Validate ACTA2, Runx2, and BMP2 changes |
| Luciferase reporter assay | Transcriptional activity of promoters | Test NONO repression of BMP2 promoter |
| miRNA mimic/inhibitor | MicroRNA function | Study miR-29a-5p effects on osteogenic transformation |
| Proteasome activity assay | Protein degradation capacity | Evaluate PA200 effects on myofibroblast differentiation |
Transcriptomic profiling of differentiation states
RNA sequencing can quantify smooth muscle markers such as ACTA2 and SM22-alpha alongside osteogenic markers like Runx2 and Osterix to determine whether a candidate gene suppresses kidney smooth muscle cell differentiation. Comparing knockout, overexpression, and wild-type cells reveals gene expression programs downstream of NONO, GDF10, or miR-29a-5p.
Calcification and mineralization assays
Alizarin red and von Kossa staining measure calcium deposition in vascular smooth muscle cell cultures, providing a functional readout of whether negative regulation is intact. These assays are typically combined with high-phosphate or BMP2 stimulation to provoke osteogenic conversion.
Protein interaction and proteomic analysis
Co-immunoprecipitation and mass spectrometry can identify proteins that interact with NONO or PA200, revealing how paraspeckle and proteasome complexes enforce negative regulation. Proteomic profiling of differentiated versus non-differentiated cells can uncover novel suppressors of smooth muscle differentiation.
Imaging of vascular remodeling
Immunofluorescence and confocal imaging of smooth muscle markers and nuclear factors such as FoxO3a or EGR2 allow spatial assessment of differentiation status in kidney and fistula tissues. Temporal imaging after Notch activation can reveal how timing influences arteriovenous fistula maturation.
How CRISPR Can Be Used to Study GO:2000357 negative regulation of kidney smooth muscle cell differentiation
Knockout
CRISPR knockout of candidate negative regulators such as NONO, GDF10, or FoxO3a in kidney vascular smooth muscle cells can test whether their loss increases smooth muscle differentiation or osteogenic conversion. Knockout models are essential for establishing causality in GO:2000357.
Point Mutation
Point mutations can disrupt specific DNA-binding domains or phosphorylation sites in transcription factors like FoxO3a or EGR2, allowing precise dissection of which residues mediate negative regulation of kidney smooth muscle cell differentiation. Point mutation of microRNA binding sites can also validate miR-29a-5p targets.
Knock-in
Knock-in of tagged versions of NONO or PA200 enables tracking of protein localization and interaction partners in live cells, clarifying how paraspeckle and proteasome complexes regulate differentiation. Knock-in of reporter genes under smooth muscle promoters provides a readout of differentiation status.
Overexpression
Overexpression of GDF10 or NONO can test whether increasing negative regulator levels prevents calcification or osteogenic conversion in kidney smooth muscle cells. Overexpression models are useful for gain-of-function studies and for validating therapeutic candidates.
How EDITGENE Supports negative regulation of kidney smooth muscle cell differentiation Research
Researchers studying negative regulation of kidney smooth muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in suppressing or promoting smooth muscle phenotype switching. Establishing causality requires precise genetic tools that can remove, modify, or amplify gene function in relevant kidney and vascular cell models. EDITGENE provides end-to-end CRISPR services tailored to these experimental needs.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of kidney smooth muscle cell differentiation research.
Frequently Asked Questions About negative regulation of kidney smooth muscle cell differentiation
What is GO:2000357?
GO:2000357 is the Gene Ontology term for negative regulation of kidney smooth muscle cell differentiation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of kidney smooth muscle cell differentiation.
What genes are involved in negative regulation of kidney smooth muscle cell differentiation?
Key genes include NONO, which represses BMP2 transcription, GDF10, a negative regulator of vascular calcification, miR-29a-5p, FoxO3a, PA200, Notch receptors, and EGR2.
Why is negative regulation of kidney smooth muscle cell differentiation important?
It protects against osteogenic conversion of vascular smooth muscle cells, which contributes to vascular calcification in chronic kidney disease and affects arteriovenous fistula maturation.
How does NONO regulate kidney smooth muscle cell differentiation?
NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription, thereby reducing osteogenic signaling that would otherwise drive smooth muscle phenotype switching.
What is the role of GDF10 in vascular calcification?
GDF10 acts as a negative regulator of vascular calcification, opposing the phenotypic switch that leads to mineral deposition in smooth muscle lineage cells.
How is miR-29a-5p involved in chronic kidney disease calcification?
miR-29a-5p is involved in osteogenic phenotype transformation and cellular regulation of vascular smooth muscle cells, influencing calcification in chronic kidney disease.
Can CRISPR be used to study negative regulation of kidney smooth muscle cell differentiation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes such as NONO, GDF10, and FoxO3a in kidney and vascular cells.
What experimental models are used to study this process?
Common models include vascular smooth muscle cell cultures, calcification assays, knockout and overexpression cell lines, and arteriovenous fistula models for remodeling studies.
What diseases are linked to loss of negative regulation of kidney smooth muscle cell differentiation?
Vascular calcification, chronic kidney disease complications, arteriovenous fistula maturation failure, and fibrotic remodeling are linked to dysregulation of this process.
How does FoxO3a relate to smooth muscle and myofibroblast differentiation?
FoxO3a acts as a negative regulator of cardiac myofibroblast conversion induced by TGF-beta1, providing a model for transcription factor-mediated suppression of mesenchymal differentiation.
Conclusion
GO:2000357, negative regulation of kidney smooth muscle cell differentiation, represents a critical protective process that prevents inappropriate phenotypic switching of vascular smooth muscle cells in the kidney. Molecular brakes such as NONO, GDF10, miR-29a-5p, FoxO3a, and PA200 enforce this negative regulation, and their dysfunction is linked to vascular calcification, chronic kidney disease complications, and fistula maturation failure. CRISPR-based knockout, point mutation, knock-in, and overexpression models are indispensable for dissecting the causal roles of these regulators. By combining precise gene editing with transcriptomic, proteomic, and imaging readouts, researchers can advance understanding of this ontology term and translate findings into therapeutic strategies for kidney vascular disease.
References
- 1. Lu Y et al.. 2024. Paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription.. Kidney Int 105(6):1221-1238 PMID: 38417578
- 2. Lips P. 2006. Vitamin D physiology.. Prog Biophys Mol Biol 92(1):4-8 PMID: 16563471
- 3. Platko K et al.. 2024. GDF10 is a negative regulator of vascular calcification.. J Biol Chem 300(11):107805 PMID: 39307303
- 4. Welk V et al.. 2019. Proteasome activator PA200 regulates myofibroblast differentiation.. Sci Rep 9(1):15224 PMID: 31645612
- 5. Deng H et al.. 2022. Mechanisms of miR-29a-5p involvement in osteogenic phenotype transformation and cellular regulation of vascular smooth muscle and thus influencing calcification in VSMCs in chronic kidney disease.. Cell Mol Biol (Noisy-le-grand) 68(7):123-128 PMID: 36495508
- 6. Guo Q et al.. 2022. Temporal regulation of notch activation improves arteriovenous fistula maturation.. J Transl Med 20(1):543 PMID: 36419038
- 7. Vivar R et al.. 2020. Role of FoxO3a as a negative regulator of the cardiac myofibroblast conversion induced by TGF-β1.. Biochim Biophys Acta Mol Cell Res 1867(7):118695 PMID: 32169420
- 8. Song A et al.. 2026. EGR2 promotes vascular smooth muscle cell differentiation and proliferation in outward remodeling during arteriovenous fistula maturation.. Biochim Biophys Acta Mol Basis Dis 1872(8):168390 PMID: 42526818
